FLT3 and acute promyelocytic leukemia: In some FLT3-ITD+ APL patients, it was observed that the presenting clone at relapse lost the FLT3-ITD mutations or other passenger mutations that were present at diagnosis, indicating the existence of a pre-leukemic PML-RARA-expressing clone that survived RA/chemotherapy and reinitiated APL [37].